For 2023, Ipsen reports a 13% drop in business EPS to 9.15 euros, and a 4.9-point decline in business operating margin to 32% 'in a context of increased R&D investments mainly linked to recent acquisitions'.

At 3.13 billion euros, the pharmaceutical company's total sales rose by 6.7% at constant exchange rates (+3.4% on a reported basis), driven by the performance of growth platforms and the contribution of new drugs.

For 2024, Ipsen is targeting total sales growth of over 6% at constant exchange rates and an operating margin of around 30%, including the impact of four potential launches and a strengthened R&D product portfolio.

Copyright (c) 2024 CercleFinance.com. All rights reserved.